Bioinformatics analysis reveals the potential target of rosiglitazone as an antiangiogenic agent for breast cancer therapy
oleh: Adam Hermawan, Herwandhani Putri
| Format: | Article |
|---|---|
| Diterbitkan: | BMC 2022-09-01 |
Deskripsi
Highlights Recent studies have focused on the development of indirect angiogenesis inhibitors. Bioinformatics-based identification of potential rosiglitazone target genes to inhibit breast cancer angiogenesis. FABP4, ADIPOQ, PPARG, PPARGC1A, CD36, and CREBBP are potential targets of rosiglitazone.